Cardiology (all articles)
Consensus: CT and MR Imaging Prior to Transcatheter Aortic Valve Implantation
8 Sep, 2019 | 23:55h | UTC
Systematic Review: Antiarrhythmics for Maintaining Sinus Rhythm after Cardioversion of Atrial Fibrillation
6 Sep, 2019 | 09:03h | UTCAntiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation – Cochrane Library (free)
#ESCCongress – Study: Cancer Now Leading Cause of Death in High-income Countries
4 Sep, 2019 | 09:32h | UTCVariations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study – The Lancet (free for a limited period – registration required)
Related Study: Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study – The Lancet (free for a limited period – registration required)
Commentaries: Cancer now leading cause of death in high-income countries — while heart disease burden persists in low-income and middle-income countries – The Lancet (free) AND Cardiovascular Disease Leading Cause of Death World-Wide, but Cancer Rising Cause in Rich Countries: Study – McMaster University (free) AND Cancer ‘biggest middle-age killer in rich nations’ – BBC (free) AND Cancer overtakes heart disease as biggest rich-world killer – Reuters (free) AND Cancer now tops heart disease as the No. 1 cause of death in these countries – CNN (free)
Related Commentary on Twitter
Presenting now #ESCCongress—#CVD remains leading cause of mortality globally, accounting for 40% of deaths, but in HIC, #cancer is now responsible for twice as many deaths: findings from #PUREStudy
Free to read with reg until Sept 10 #LancetCardiology https://t.co/iXSfIio77D pic.twitter.com/eHEJ0kWWfa
— The Lancet (@TheLancet) September 3, 2019
Resistant Hypertension Updated Guidelines
4 Sep, 2019 | 08:55h | UTCResistant Hypertension Updated Guidelines – Current Cardiology Reports (free)
Related: AHA Guideline: Resistant Hypertension (free) AND 7th Brazilian Guideline of Arterial Hypertension: Chapter 13 – Resistant Arterial Hypertension (free)
Guidelines on the Management of Patients Developing QT Prolongation on Antipsychotic Medication
4 Sep, 2019 | 09:00h | UTC
How to Diagnose Heart Failure with Preserved Ejection Fraction: The HFA–PEFF Diagnostic Algorithm
4 Sep, 2019 | 08:58h | UTC
Related Commentary on Twitter (Thread – Click for more)
1/8 Twitter editorial by coordinator of the HFpEF study @rudolf_deboer on new #HFA_ESC position paper ‘How to Diagnose #HF w/ Preserved Ejection Fraction – The HFA-PEFF-SCORE" https://t.co/n9VOls5ITE pic.twitter.com/XE3ao0Rq6w
— European Society of Cardiology Journals (@ESC_Journals) August 31, 2019
#ESCCongress – [Not Published Yet] Randomized Trial: Oxygen is Neither Beneficial nor Harmful in Patients with Acute Coronary Syndrome
4 Sep, 2019 | 08:40h | UTCNews Release: Oxygen is neither beneficial nor harmful in patients with acute coronary syndrome – European Society of Cardiology (free)
Commentary: Supplemental Oxygen Fails Once Again in ACS Patients: NZOTACS – TCTMD (free)
Related: Guideline: Oxygen Therapy for Acutely Ill Medical Patients (free) AND Systematic Review: Effects of Hyperoxia in Acutely Ill Patients(free) AND Meta-Analysis: Liberal vs Conservative Oxygen Therapy in Acutely ill Adults (link to abstract and commentary)
#ESCCongress – [Abstract Only] Randomized Trial Supports Oral Anticoagulant Monotherapy for Patients with Atrial Fibrillation and Stable Coronary Disease
3 Sep, 2019 | 01:26h | UTCAntithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD – TCTMD (free) AND Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease – AFIRE – American College of Cardiology (free)
Related: Meta-Analysis of Oral Anticoagulant Monotherapy as an Antithrombotic Strategy in Patients With Stable Coronary Artery Disease and Nonvalvular Atrial Fibrillation – American Journal of Cardiology (link to abstract – $ for full-text)
#ESCCongress – [Abstract Only] Randomized Trial: PCI vs. CABG in Patients with Three-vessel or Left Main Coronary Artery Disease
3 Sep, 2019 | 01:24h | UTCPercutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial – The Lancet (link to abstract – $ for full-text)
Commentary: Bypass surgery and coronary stenting yield comparable 10-year survival – European Society of Cardiology (free)
Related Meta-Analysis: Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease (link to abstract) AND Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis (free)
Related Commentary on Twitter
SYNTAX extended survival: 10yr all cause death PCI vs CABG:
❤️no significant difference in all cause death (24%CABG/27%PCI)
❤️CABG better than PCI for 3VD (21%CABG/28%PCI)
❤️no significant difference in LMS diseaseImpressive 94% FU.https://t.co/X4g9WgTBXI#ESCCongress pic.twitter.com/M7halGNnsv
— Sarah Hudson (@sarahhudsonuk) September 2, 2019
#ESCCongress – Observational Study Finds Metabolic Surgery May Reduce the Risk of Death and Cardiovascular Complications in Diabetic Patients
3 Sep, 2019 | 01:22h | UTCAssociation of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity – JAMA (free for a limited period)
Editorial: The Role of Bariatric Surgery in Managing the Macrovascular Complications of Obesity-Related Type 2 Diabetes (free for a limited period)
Commentaries: Weight-Loss Surgery Associated with 40% Reduction in Risk of Death and Heart Complications in Patients with Diabetes and Obesity, Study Shows – Cleveland Clinic (free) AND Fewer cardiovascular events seen in diabetics after weight-loss surgery – Reuters (free) AND Metabolic Surgery Improves CV Outcomes in Patients With Diabetes, Obesity – American College of Cardiology (free) AND Weight-Loss Surgery May Reduce Heart Risks in People With Type 2 Diabetes – The New York Times (10 articles per month are free)
Related Studies: Observational Study Links Bariatric Surgery to Lower Mortality but Higher Risk of Adverse Events (link to abstract) AND Association of Bariatric Surgery vs Usual Care Obesity Management With All-Cause Mortality (free study and commentaries)
#ESCCongress – WHO Cardiovascular Disease Risk Charts: Revised Models to Estimate Risk in 21 Global Regions
3 Sep, 2019 | 01:16h | UTCInvited Commentary: Cardiovascular disease risk prediction models: challenges and perspectives (free)
Related Commentary on Twitter
Presenting now at #ESCCongress—@WHO #cardiovasculardisease risk charts: revised models to estimate risk in 21 global regions #OpenAccess #LancetCardiology https://t.co/bI3qFnYnB3 pic.twitter.com/KDzVsIuKfu
— The Lancet Global Health (@LancetGH) September 2, 2019
#ESCCongress – Randomized Trial: A Community-based Comprehensive Intervention to Reduce Cardiovascular Risk in Hypertension
3 Sep, 2019 | 01:17h | UTCA community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial – The Lancet (free registration required)
Commentaries: Non-physician health workers lead new approach to lowering risk of world’s number one cause of death – The Lancet (free) AND Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4 – TCTMD (free) AND It takes a community to lower cardiovascular risk – McMaster University (free)
Related Commentary on Twitter
Non-physician health workers lead new approach to lowering risk of world’s number 1 cause of death, #cardiovasculardisease: HOPE 4, cluster-randomised controlled trial
Presenting now at #ESCCongress & free to read with reg until Sept 10 #LancetCardiology https://t.co/XS3tjVbHSH pic.twitter.com/LxvqDeQrVS
— The Lancet (@TheLancet) September 2, 2019
#ESCCongress – 2019 ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes
2 Sep, 2019 | 01:20h | UTCNews Release: Pollution and noise reduction advised in ESC guidelines on chronic coronary syndromes (free)
Related Commentary on Twitter
JUST RELEASED: 2019 #ESCGuidelines for Chronic Coronary Syndromes – what's new? what has changed? what are the 2019 new major recommendations? https://t.co/wPPZCYdRfH
@escardio #ESCCongress #ESCCoT #cardiotwitter pic.twitter.com/RBhIKgV9Uq
— European Society of Cardiology (@escardio) August 31, 2019
#ESCCongress – 2019 ESC Guidelines for the Diagnosis and Management of Acute Pulmonary Embolism
2 Sep, 2019 | 01:19h | UTC
Related Commentary on Twitter
JUST RELEASED: 2019 #ESCGuidelines for Acute Pulmonary Embolism – what's new? what has changed? what are the main 2019 recommendations? https://t.co/nyLf7eWk5G@escardio #ESCcongress #ESCCoT #cardiotwitter pic.twitter.com/DEFBMKdwcO
— European Society of Cardiology (@escardio) August 31, 2019
#ESCCongress – 2019 ESC Guidelines for the Management of Patients with Supraventricular Tachycardia
2 Sep, 2019 | 01:17h | UTC
Related Commentary on Twitter
JUST RELEASED: 2019 #ESCGuidelines for the management of Supraventricular Tachycardia – what's new? what has changed? what are the main 2019 recommendations? https://t.co/A3Y15T3Dy8#ESCcongress #cardiotwitter pic.twitter.com/GVkMoOvYQQ
— European Society of Cardiology (@escardio) August 31, 2019
#ESCCongress – 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
2 Sep, 2019 | 01:15h | UTC
Related Commentary on Twitter
JUST RELEASED: 2019 #ESCGuidelines for the management of Dyslipidaemias – what's new? what has changed? what are the main 2019 recommendations? https://t.co/aBU1PkGc2k
@escardio #ESCCongress #ESCCoT #cardiotwitter pic.twitter.com/NChfhPNXDq
— European Society of Cardiology (@escardio) August 31, 2019
#ESCCongress – [Abstract Only] Randomized Trial: Complete Revascularization Superior to Culprit-lesion-only PCI in Patients with ST-segment Elevation Myocardial Infarction (STEMI) and Multivessel Coronary Artery Disease
2 Sep, 2019 | 01:11h | UTCComplete Revascularization with Multivessel PCI for Myocardial Infarction – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Complete Versus Culprit-Only Revascularization Strategies to Treat Multivessel Disease After Early PCI for STEMI – COMPLETE – American College of Cardiology (free) AND Complete revascularisation is superior to culprit-lesion only intervention – European Society of Cardiology (free)
Related Cochrane Review: Complete versus culprit-only revascularisation in ST elevation myocardial infarction with multi-vessel disease – Cochrane Library (free)
Related Meta-analysis: Complete Revascularization During Primary Percutaneous Coronary Intervention Reduces Death and Myocardial Infarction in Patients With Multivessel Disease: Meta-Analysis and Meta-Regression of Randomized Trials – JACC: Cardiovascular Interventions (free)
Related Commentary on Twitter
#COMPLETE trial results out at #ESCCongress! Complete revascularisation of multivessel coronary disease after STEMI superior to culprit-only PCI. Reduction in composite of CV death/MI from 10.5% to 7.8% at 3yrs – driven by lwr incidence of MI. https://t.co/STBfNuGzDY pic.twitter.com/VNsaQArG0x
— Tom Cahill (@tomjcahill) September 1, 2019
#ESCCongress – 2019 ESC Guidelines on Diabetes, Pre-diabetes, and Cardiovascular Diseases
2 Sep, 2019 | 01:14h | UTC
Related Commentary on Twitter
JUST RELEASED: 2019 #ESGuidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases – what's new? what has changed? what are the main 2019 recommendations? https://t.co/FY6xt34jNo#ESCCongress #cardiotwitter pic.twitter.com/q1HBPfRO5f
— European Society of Cardiology (@escardio) August 31, 2019
#ESCCongress – Randomized Trial Suggests Maximum-fixed Energy Shocks (360-360-360 J) are More Effective for Cardioverting Atrial Fibrillation
2 Sep, 2019 | 01:12h | UTCMaximum-fixed energy shocks for cardioverting atrial fibrillation – European Heart Journal (free)
Commentary: Comparison of High vs. Escalating Shocks – CHESS – American College of Cardiology (free)
Related Commentary on Twitter
Maximum-fixed energy shocks (360-360-360J) were more effective and equally safe when compared with low-escalating energy shocks (125-150-200J) for cardioverting atrial fibrillation https://t.co/RkYCNILvck
@escardio @TomLuscher #EHJ #ESCcongress #freeaccess pic.twitter.com/3ZxS5Xx2Ok
— European Society of Cardiology Journals (@ESC_Journals) August 31, 2019
#ESCCongress – [Not Published Yet] Randomized Trial Supports Single High-sensitive Troponin Measurement to Rule out Myocardial Infarction
2 Sep, 2019 | 01:06h | UTCCommentaries: HiSTORIC Trial Supports Single-Test Rule-Out of MI Using High-Sensitivity Troponin – TCTMD (free) AND Risk-Based Thresholds for hs-Troponin I Safely Speed MI Rule-Out – MedPage Today (free registration required) AND HISTORIC: Early Rule-Out Strategy Using High-Sensitivity Cardiac Troponin I Reduced Length of Stay, Hospital Readmissions in Suspected ACS Patients – American College of Cardiology (free)
Related Studies: Randomized Trial: High-Sensitivity Troponin in the Evaluation of Suspected Acute Coronary Syndrome (free study and commentaries) AND Cohort Study: The Introduction of High-sensitive Troponins Had No Impact on Survival (free study and commentaries)
Related Commentary on Twitter
In an RCT of 31,492 patients with suspected acute coronary syndrome, a rule out pathway using a hs-TnI risk stratification threshold of 5ng/L reduced length of stay by 3.3hrs (57% ⬆️ in ED discharge) with no evidence of harm at one year #ESCCongress #HiSTORIC #troponin pic.twitter.com/5hTUcxAyLF
— Andrew Chapman (@chapdoc1) September 1, 2019
#ESCCongress – [Not Published Yet] Randomized Trial: SGLT2 inhibitors Seems Beneficial for Heart Failure Even in Nondiabetics
2 Sep, 2019 | 01:09h | UTCCommentaries: Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction – DAPA-HF – American College of Cardiology (free) Dapagliflozin reduces death and hospitalisation in patients with heart failure – European Society of Cardiology (free)
Related Commentary on Twitter
DAPA-HF trial at #ESCCongress: significant reduction of events in HFrEF patients by dapagliflozine. Half of the 5744 pts had diabetes, the others did not: same effect in both groups.
SGLT2 inhibitors just better diuretics or the "statins of HF"?@escardio #cardiotwitter pic.twitter.com/nzTv58d0cd— Stephan Achenbach (@Steph_Achenbach) September 1, 2019
#ESCCongress – [Abstract Only] Randomized Trial: Angiotensin–Neprilysin Inhibition Not Beneficial for Heart Failure with Preserved Ejection Fraction
2 Sep, 2019 | 01:03h | UTCAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: PARAGON-HF: Sacubitril-Valsartan in HFpEF Patients Did Not Result in Significantly Lower Rates of Hospitalizations, Death – American College of Cardiology (free)
Related Commentary on Twitter
#PARAGON-HF released!#ESCCongress Sacubitril–valsartan did not result in a significantly lower rate of total hospitalizations for heart failure & death from CV causes among patients with heart failure and an ejection fraction of >|=45%
? https://t.co/Q7rwiDyLT4… pic.twitter.com/ktumqXFrO8— Dr. Martha Gulati (@DrMarthaGulati) September 1, 2019
#ESCCongress – Observational Study: A Low High-sensitive Troponin has a Negative Predictive Value of 99.8% for Myocardial Infarction or Cardiac Death Within 30 days in Patients with Suspected Acute Coronary Syndrome and at Least 2 Hours of Symptoms
2 Sep, 2019 | 01:04h | UTC
#ESCCongress – Cohort Study: Cardiovascular Disease Patients May Benefit More from Exercise than Healthy People
2 Sep, 2019 | 00:58h | UTCNews Release: Cardiovascular disease patients benefit more from exercise than healthy people – European Society of Cardiology (free)
#ESCCongress – [Abstract Only] Randomized Trial: Prasugrel Better than Ticagrelor for Patients with Acute Coronary Syndrome with Planned Invasive Evaluation
2 Sep, 2019 | 00:59h | UTCTicagrelor or Prasugrel in Patients with Acute Coronary Syndromes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Prasugrel cuts ischaemic events in acute coronary syndrome patients – European Society of Cardiology (free) AND Prasugrel Bests Ticagrelor in ACS Patients Heading to PCI: ISAR-REACT 5 – TCTMD (free) AND Intracoronary Stenting and Antithrombotic Regimen 5 – ISAR-REACT 5 – American College of Cardiology (free)
Related Commentary on Twitter
ISAR-REACT 5 presented at #ESCCongress and published in @NEJM:
4000 pats with ACS randomized to Ticagrelor vs Prasugrel:
comp endpoint (death/MI/stroke) 9.3% for Tica, 6.9% for Prasugrel (driven by MI), similar bleeding.well, thats something! https://t.co/JcLkJTRhAw pic.twitter.com/PNxdsM0lik
— Konstantin Krychtiuk (@krychtiukmd) September 1, 2019